The high universality of RNAs enables researchers to design different structures and bioactive RNAs capable of performing specific functions.[47] Targeting the AZIN1 editing site with ASOs specifically inhibits tumor incidence and growth in patient‐derived xenograft (PDX) models.[48] Silencing SNORA23 with ASOs suppresses tumor growth, dissemination of tumor cells, and liver metastasis.[49]. The gene discussed is AZIN1; the disease is neoplasm.